Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Dye, John M ^a   Wu, Hua ^b   Hooper, Jay W ^a   Khurana, Surender ^c   Kuehne, Ana I ^a   Coyle, Elizabeth M ^c   Ortiz, Ramon A ^a   Fuentes, Sandra ^c   Herbert, Andrew S ^a   Golding, Hana ^c   Bakken, Russell A ^a   Brannan, Jennifer M ^a   Kwilas, Steve A ^a   Sullivan, Eddie J ^b   Luke, Thomas C ^d   Smith, Gale ^e   Glenn, Gregory ^e   Li, Wenfang ^f   Ye, Ling ^f   Yang, Chinglai ^f   Compans, Richard W ^f   Tripp, Ralph A ^g   Jiao, Jin An ^b   more..

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SAB Biotherapeutics ^*  (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d NAVAL MEDICAL RESEARCH CENTER   (United States)

^e NOVAVAX INC   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ANIMAL; BAGG ALBINO MOUSE; BLOOD; BOVINE; DISEASE MODEL; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; PASSIVE IMMUNIZATION; SERODIAGNOSIS; SURFACE PLASMON RESONANCE; TRANSGENIC ANIMAL; TREATMENT OUTCOME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, VIRAL; CATTLE; DISEASE MODELS, ANIMAL; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SURFACE PLASMON RESONANCE; TREATMENT OUTCOME;

EID: 84964658344     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24897     Document Type: Article

References (32)

1. Feldmann, H., Jones, S., Klenk, H. D. & Schnittler, H. J. Ebola virus: from discovery to vaccine. Nat Rev Immunol 3, 677-685 (2003).
2. Feldmann, H., Slenczka, W. & Klenk, H. D. Emerging and reemerging of filoviruses. Arch Virol [Suppl] 11, 77-100 (1996).
3. Baize, S. et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virusinfected patients. Nature Medicine 5, 423-426 (1999).
4. Leroy, E. M. et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355, 2210-2215 (2000).
5. Hartman, A. L., Towner, J. S. & Nichol, S. T. Ebola and marburg hemorrhagic fever. Clinics in Laboratory Medicine 30, 161-177 (2010).
6. Parren, P. W. et al. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Viro l76(12), 6408-12 (2002).
7. Oswald, W. B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLos Pathog 3(1), p. e9 (2007).
8. Dye, J. M. et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109(13), p. 5034-9 (2012).
9. Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53 (2014).
10. Zhang, Y., Li, D., Jin, X. & Huang, Z. Fighting Ebola with ZMapp: spotlight on plant-made antibody. Science China Life sciences 57, 987-988 (2014).
11. Qiu, X. et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4, 138ra181, doi: 10.1126/scitranslmed.3003876 (2012).
12. McCarthy, M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349, doi: 10.1136/bmj.g5488. (2014).
13. Mupapa, K. et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179 Suppl 1, S18-23 (1999).
14. Sadek, R. F., Khan, A. S., Stevens, G., Peters, C. J. & Ksiazek, T. G. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 179 Suppl 1, S24-27 (1999).
15. Luke, T. C. et al. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38 (4 Suppl), e66-73, doi: 10.1097/CCM.0b013e3181d44c1e (2010).
16. Hemming, V. G. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Diagn Lab Immunol 8, 859-863 (2001).
17. Leon, G. et al. Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms. Toxicon: Official Journal of the International Society on Toxinology 76, 63-76 (2013).
18. Osther, K. et al. PASSHIV-1 treatment of patients with HIV-1 infection. A preliminary report of a phase I trial of hyperimmune porcine immunoglobulin to HIV-1. Aids 6, 1457-1464 (1992).
19. Sano, A. et al. Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle. Plos one 8, doi: 10.1371/journal.pone.0078119 (2013).
20. Matsushita, H. et al. Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production. Plos one 9, doi: 10.1371/journal.pone.0090383 (2014).
21. Kuroiwa, Y. et al. Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat Biotechnol 27, 173-181 (2009).
22. Matsushita, H. et al. Species-Specific Chromosome Engineering Greatly Improves Fully Human Polyclonal Antibody Production Profile in Cattle. PLos One 10, doi: 10.1371/ journal.pone.0130699 (2015).
23. Hooper, J. W. et al. DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med 6, 264ra162, doi: 10.1126/scitranslmed.3010082 (2014).
24. Dias, J. M. et al. A shared structural solution for neutralizing ebolaviruses. Nat Struct Mol Biol 18, 1424-1427 (2011).
25. Regules, J. A. et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine - Preliminary Report. N Engl J Med April 1, 2015, doi: 10.1056/NEJMoa1414216 (2015).
26. Khurana, S. et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2, 15ra5, doi: 10.1126/scitranslmed.3000624 (2010).
27. Khurana, S. et al. MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines. Sci Transl Med 3, 85ra48, doi: 10.1126/scitranslmed.3002336 (2011).
28. Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287(5458), 1664-1666 (2000).
29. Qiu, X. et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLos Negl Trop Dis 6(3), p. e1575, doi: 10.1371/journal.pntd.0001575 (2012).
30. Hahn, T. J. et al. Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology. Bioprocessing Journal 14, 6-15 (2015).
31. Martins, K. et al. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein. Viral Immunol 28(1), p. 62-70 (2015).
32. Bray, M. et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178(3), p. 651-61 (1998).